AngioDynamics (ANGO) : Lapides Asset Management scooped up 700 additional shares in AngioDynamics during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 638,000 shares of AngioDynamics which is valued at $9,984,700.AngioDynamics makes up approximately 1.64% of Lapides Asset Management’s portfolio.
Other Hedge Funds, Including , Royce Associates Lp boosted its stake in ANGO in the latest quarter, The investment management firm added 31,308 additional shares and now holds a total of 752,109 shares of AngioDynamics which is valued at $11,770,506. AngioDynamics makes up approx 0.07% of Royce Associates Lp’s portfolio. First Trust Advisors Lp sold out all of its stake in ANGO during the most recent quarter. The investment firm sold 33,099 shares of ANGO which is valued $504,760.Great West Life Assurance Co Can boosted its stake in ANGO in the latest quarter, The investment management firm added 31,244 additional shares and now holds a total of 34,085 shares of AngioDynamics which is valued at $517,751.
AngioDynamics opened for trading at $15.93 and hit $16.09 on the upside on Monday, eventually ending the session at $15.99, with a gain of 1.72% or 0.27 points. The heightened volatility saw the trading volume jump to 1,82,852 shares. Company has a market cap of $582 M.
On the company’s financial health, AngioDynamics reported $0.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 13, 2016. Analyst had a consensus of $0.16. The company had revenue of $93.40 million for the quarter, compared to analysts expectations of $88.64 million. The company’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS.
AngioDynamics Inc. designs manufactures and sells a range of medical surgical and diagnostic devices used by professional healthcare providers for vascular access for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include fluid management venous thrombus management as well as other core products. The Company’s BioFlo products incorporate Endexo technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its microwave ablation products its radiofrequency ablation (RFA) and its NanoKnife product lines.